RESEARCHANDMARKETS

Brochure

More information from http://www.researchandmarkets.com/reports/2228908/

Risk - Reward of Developing a Herceptin Biosimilar - A Thorough Assessment

Description:

Herceptin exclusivity is expiring in major geographies and many Biosimilar players (both experienced and new entrant) are looking to have a share of this potential \$6billion pie. Herceptin sales are critical to Roche as it comprise about 15% of its cumulative Pharma sales. While eying for this potential lucrative opportunity, there are several risks and barriers that Biosimilar players should be aware. The report – "Risk – Reward of Developing a Herceptin biosimilar – A thorough assessment" looks into several aspects of potential opportunity size for Biosimilar players, with regard to:

- European Experience of Biosimilars
- Current market positioning of Herceptin across geography
- Different technologies deployed by biosimilar players
- Competition Pipeline of Biosimilar and Biobetters targeting Herceptin
- Potential Market Expansion post expiry of Market Exclusivity
- Defense Strategies deployed by Roche
- Ongoing Clinical trials and their impact on Market Opportunity
- Global Regulatory Process and Hurdles
- Risk/Reward profile of developing Herceptin biosimilar

Contents:

- 1. Executive Summary
- 2. European experience of Biosimilar launch
- Pricing
- Market share dynamics
- 3. Introduction- Herceptin
- Geography-wise Sales Forecast until patent expiry
- Patent expiries in major geographies
- Pricing in major geographies
- Penetration in major emerging markets
- Expected market expansion post patent expiry
- Ongoing Clinical trials on Herceptin

4. About the biosimilar space

- Different technologies deployed by biosimilar players
- Partnering deals in biosimilar
- Cost of developing biosimilar/biobetter
- Comparison USFDA and EUROPE biosimilar guideline
- Requirement of Analytical methods
- Interchangeability and substitution
- Regulatory review process for biosimilar- Principle and Concepts
- Bridging Studies- A way to reduce the launch timeline in multiple geographies
- Importance of post-marketing safety in Non-ICH countries
- A brief on biosimilar approval guidelines in geographies other than US and Europe

5. Pipeline of Herceptin Biosimilar and Biobetters

- Ongoing Clinical trials on Herceptin biosimilar/biobetter
- A brief on companies developing Herceptin biosimilar

RESEARCHANDMARKETS

- Financial capability
- Technical capability
- 6. Opportunities and Threats for Herceptin Biosimilar
- Defense strategy by Roche to woo away biosimilar threat in global markets and Emerging markets
- Major clinical trials on Herceptin- potential impact on its future sales
- Physician's and Payers adaptation for using Biosimilar Mab
- Competitive threats Upcoming biobetters and novel biologics in HER2+ve Breast cancer and Gastric cancer
- 7. Our view on Risk/Reward profile of developing Herceptin Biosimilar
- 8. About the biosimilar space
- Different technologies deployed by biosimilar players
- Partnering deals in biosimilar
- Cost of developing biosimilar/biobetter
- Comparison USFDA and EUROPE biosimilar guideline
- Requirement of Analytical methods
- Interchangeability and substitution
- Regulatory review process for biosimilar- Principle and Concepts
- Bridging Studies- A way to reduce the launch timeline in multiple geographies
- Importance of post-marketing safety in Non-ICH countries
- A brief on biosimilar approval guidelines in geographies other than US and Europe
- 9. Pipeline of Herceptin Biosimilar and Biobetters
- Ongoing Clinical trials on Herceptin biosimilar/biobetter
- A brief on companies developing Herceptin biosimilar
- Financial capability
- Technical capability

Ordering: Order Online - http://www.researchandmarkets.com/reports/2228908/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

RESEARCHANDMARKETS Page 1 of 2

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

<i>r</i> 1	ra	er	Int	or	m	211	OI	٦
u	ıч			OI.		au	u	п

Please verify that the product information is correct and select the format(s) you require.

Product Name: Risk – Reward of Developing a Herceptin Biosimilar – A Thorough Assessment

Web Address: http://www.researchandmarkets.com/reports/2228908/

Office Code: OC8DIRROLTVTVZ

Product Formats

Please select the product formats and quantity you require:

The production	mate and quantity you require
	Quantity
Electronic (PI Single User:	DF) - €1,490
Electronic (PI Site License:	DF) - €2,979
Electronic (PI Enterprisewio	
Zitter prisewi	
Contact Information	
Please enter all the informati	ion below in BLOCK CAPITALS
Title:	Mr
First Name:	Last Name:
Email Address: *	
Job Title:	
Organisation:	
Address:	
City:	
Postal / Zip Code:	
Country:	
Phone Number:	
Fax Number:	

^{*} Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

RESEARCHANDMARKETS Page 2 of 2

Payment Information

ase indicate the payment method you	would like to use by selecting	the appropriate box.				
Pay by credit card:	American Express	American Express				
	Diners Club					
	Master Card					
	Visa					
	Cardholder's Name					
	Cardholder's Signature					
	Expiry Date					
	Card Number					
	CVV Number					
	Issue Date (for Diners Club only)					
Pay by check:	Please post the check, a	ccompanied by this form, to:				
	Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland.					
Pay by wire transfer:	Please transfer funds to	Please transfer funds to:				
	Account number	833 130 83				
	Sort code	98-53-30				
	Swift code	ULSBIE2D				
	IBAN number	IE78ULSB98533083313083				
	Bank Address	Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.				
If you have a Marketing Code pleas	se enter it below:					
Marketing Code:						

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp